Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31171 | 0.76 | CYP2A6 (0.69) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL1970199 | 0.76 | PDE2A (0.52) | PDE2A | |
| SCHEMBL4956384 | 0.76 | CYP2A6 (0.69) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL13485733 | 0.74 | ALDH1A1 (0.58) | ALDH1A1PDE2A | |
| Hydrochloric Acid SCHEMBL28807787 | 0.73 | CYP2A6 (0.65) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| Water SCHEMBL29197442 | 0.73 | CYP2A6 (0.65) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| Phosphine SCHEMBL27461872 | 0.73 | CYP2A6 (0.65) | CYP2A6HSD17B10ALDH5A1ABATALDH1A1 | |
| SCHEMBL30462334 | 0.72 | ALDH1A1 (0.48) | CYP2A6ALDH1A1KDM4ETRIM24TRIM33 | |
| SCHEMBL14320530 | 0.72 | ALDH1A1 (0.48) | CYP2A6ALDH1A1KDM4ETRIM24TRIM33 | |
| SCHEMBL17431624 | 0.70 | NFE2L2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250334881-A1 | RADIATION SENSITIVE RESIN COMPOSITION, PATTERN FORMING METHOD, RADIATION SENSITIVE ACID GENERATOR, AND ACID DIFFUSION CONTROL AGENT | JSR CORPORATION (JP) | 2025-10-30 | — | — | US | disclosed |
| CN-119707931-A | Intermediate and synthesis method of 1- (1-oxo-1, 2-dihydro-phthalazin-6-yl) cycloalkyl-1-carboxamide derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州(北京)生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2023223624-A1 | RADIATION SENSITIVE RESIN COMPOSITION, PATTERN FORMING METHOD, RADIATION SENSITIVE ACID GENERATOR, AND ACID DIFFUSION CONTROL AGENT | JSR株式会社 | 2023-11-23 | — | — | WO | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110312719-B | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3321257-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3321257-A1 | SUBSTITUTED 5-AMINOTHIENO[2,3-C]PYRIDAZINE-6-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9868746-B2 | Substituted 5-aminothieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868746-B2 | Substituted 5-aminothieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868746-B2 | Substituted 5-aminothieno[2,3-C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2018-01-16 | — | — | US | disclosed |
| CN-1930153-A | Pentafluorosulfanyl compounds, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| CN-1930156-A | Oxidized thioether derivatives of styryl-azoles and their use as HER tyrosine kinases inhibitors | HOFFMANN LA ROCHE (CH) | 2007-03-14 | — | — | CN | disclosed |
| EP-1725549-A1 | PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006122777-A2 | USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS | Grünenthal GmbH (DE) | 2006-11-23 | — | — | WO | disclosed |
| CN-1867567-A | 2-' (E) -2- (phenyl) vinyl-4- (arylalkoxy) -oxazole or-thiazole compounds as HER-2 tyrosine kinase inhibitors and their use in the treatment of cancer | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | CN | disclosed |
| EP-1680417-A1 | 1-'(E)-2-(PHENYL)ETHENYL-4-(ARYLALKOXY)-OXAZOLE OR -THIAZOLE COMPOUNDS AS HER-2 TYROSINE KINASES INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005095388-A1 | PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20050197370-A1 | Novel pentafluorosulfanyl compounds | HOFFMANN-LA ROCHE INC. | 2005-09-08 | — | — | US | disclosed |
| US-20050124670-A1 | Novel arylazole derivatives, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-06-09 | — | — | US | disclosed |
| WO-2005040158-A1 | 1-′(E)-2-(PHENYL) ETHENYL-4-(ARYLALKOXY)-OXAZOLE OR - THIAZOLE COMPOUNDS AS HER-2 TYROSINE KINASES INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN - LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197370-A1 | Novel pentafluorosulfanyl compounds | SF3B5, SF3B1, SF3B3 | CYP2A6 285/4885HSD17B10 308/4885ALDH5A1 210/4885 |
| US-20050124670-A1 | Novel arylazole derivatives, their manufacture and use as pharmaceutical agents | CYP3A43, CYP3A5, CYP1A1 | CYP2A6 46/4885HSD17B10 627/4885ALDH5A1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.